Johnson & Johnson (NYSE:JNJ) Holdings Boosted by MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH

MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH grew its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 99.2% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 52,629 shares of the company's stock after purchasing an additional 26,203 shares during the quarter. MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH's holdings in Johnson & Johnson were worth $8,728,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Tallon Kerry Patrick bought a new stake in Johnson & Johnson in the 4th quarter valued at about $290,000. Capital & Planning LLC raised its holdings in shares of Johnson & Johnson by 13.6% during the fourth quarter. Capital & Planning LLC now owns 1,528 shares of the company's stock valued at $221,000 after buying an additional 183 shares during the last quarter. Brighton Jones LLC boosted its position in shares of Johnson & Johnson by 13.9% during the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock worth $7,502,000 after buying an additional 6,332 shares during the period. Union Bancaire Privee UBP SA bought a new position in Johnson & Johnson in the 4th quarter worth approximately $85,886,000. Finally, Viewpoint Capital Management LLC increased its position in Johnson & Johnson by 5.1% in the 4th quarter. Viewpoint Capital Management LLC now owns 14,051 shares of the company's stock valued at $2,032,000 after acquiring an additional 681 shares during the period. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts have issued reports on the company. Bank of America reduced their price target on Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating for the company in a research report on Thursday, April 10th. Barclays reduced their price objective on shares of Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating for the company in a report on Thursday, April 17th. Leerink Partners cut shares of Johnson & Johnson from an "outperform" rating to a "market perform" rating and lowered their target price for the company from $169.00 to $153.00 in a research note on Tuesday, May 13th. Morgan Stanley upped their price target on shares of Johnson & Johnson from $164.00 to $169.00 and gave the stock an "equal weight" rating in a research note on Wednesday, April 16th. Finally, Leerink Partnrs lowered shares of Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, May 13th. Eleven equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $170.88.

Johnson & Johnson Price Performance

Johnson & Johnson stock traded down $1.61 during mid-day trading on Thursday, hitting $150.77. The company's stock had a trading volume of 8,323,506 shares, compared to its average volume of 7,967,133. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $169.99. The stock's fifty day moving average price is $154.06 and its two-hundred day moving average price is $153.67. The stock has a market capitalization of $362.76 billion, a P/E ratio of 16.77, a P/E/G ratio of 2.31 and a beta of 0.42. The company has a quick ratio of 1.03, a current ratio of 1.26 and a debt-to-equity ratio of 0.49.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.59 by $0.18. Johnson & Johnson had a return on equity of 33.46% and a net margin of 24.42%. The business had revenue of $21.89 billion for the quarter, compared to analysts' expectations of $21.65 billion. Research analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th were paid a dividend of $1.30 per share. The ex-dividend date of this dividend was Tuesday, May 27th. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.24. This represents a $5.20 dividend on an annualized basis and a yield of 3.45%. Johnson & Johnson's dividend payout ratio is currently 57.84%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.